- Home
- VNDA vs EOD Comparison
VNDA vs EOD Comparison
Compare VNDA & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- EOD
- Stock Information
- Founded
- VNDA 2002
- EOD 2007
- Country
- VNDA United States
- EOD United States
- Employees
- VNDA N/A
- EOD N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- EOD Investment Managers
- Sector
- VNDA Health Care
- EOD Finance
- Exchange
- VNDA Nasdaq
- EOD Nasdaq
- Market Cap
- VNDA 237.9M
- EOD 213.8M
- IPO Year
- VNDA 2006
- EOD N/A
- Fundamental
- Price
- VNDA $4.34
- EOD $5.29
- Analyst Decision
- VNDA Strong Buy
- EOD
- Analyst Count
- VNDA 3
- EOD 0
- Target Price
- VNDA $15.33
- EOD N/A
- AVG Volume (30 Days)
- VNDA 519.0K
- EOD 118.1K
- Earning Date
- VNDA 05-07-2025
- EOD 01-01-0001
- Dividend Yield
- VNDA N/A
- EOD 9.28%
- EPS Growth
- VNDA N/A
- EOD N/A
- EPS
- VNDA N/A
- EOD N/A
- Revenue
- VNDA $201,351,000.00
- EOD N/A
- Revenue This Year
- VNDA $16.86
- EOD N/A
- Revenue Next Year
- VNDA $39.78
- EOD N/A
- P/E Ratio
- VNDA N/A
- EOD N/A
- Revenue Growth
- VNDA 13.37
- EOD N/A
- 52 Week Low
- VNDA $3.81
- EOD $3.73
- 52 Week High
- VNDA $6.75
- EOD $4.71
- Technical
- Relative Strength Index (RSI)
- VNDA 51.79
- EOD 63.49
- Support Level
- VNDA $4.17
- EOD $5.16
- Resistance Level
- VNDA $4.41
- EOD $5.29
- Average True Range (ATR)
- VNDA 0.16
- EOD 0.08
- MACD
- VNDA 0.03
- EOD -0.00
- Stochastic Oscillator
- VNDA 73.61
- EOD 94.44
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.